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（１）B細胞系の癌は、主に Bリンパ腫及び B細胞系白血病に分類され、その癌細胞は B
細胞の分化マーカ （ーCD20等）を高発現している。その中でも、主要組織適合複合体（MHC）
の一つであるヒト白血球抗原 DR（HLA-DR）は、古くから抗体医薬開発の標的分子として
臨床試験が実施されながら、現時点でも未だ成功例が無い抗原である。一方、CD20抗体（リ
ツキシマブ）の B 細胞系腫瘍における著効は有名で、リンパ腫及び白血病において抗体医
薬が効果を発揮しうることを裏付ける代表例となっている。しかし CD20抗体においても、
不応例や再発例が存在し、さらには投与時の即時型毒性が問題となる場合もある。そこで、
HLA-DR抗体を新たに作製し、その特性解析を行い、さらにその抗体の Fc領域への変異導
入による毒性・薬効について検討した。 
 
（２）医薬品の開発においては患者の遺伝子多型による効果のバラつきが障害となりうる
が、HLA-DR 分子は最も多型を有する分子で、その数は 500 を超える。HLA-DR 抗体を医
薬品として応用する場合、膨大な多型による効果のばらつきを克服することが重要となる。 
そこで、HLA-DR に対する完全ヒト抗体を、ヒト抗体産生マウスを用いて作製し、それ
ら抗体の中から多くの HLA-DR陽性細胞を認識する抗体 HD8を選抜した。HD8抗体の解析
の結果、検査した約 50種の HLA-DR陽性細胞すべてに強く反応することを確認した。しか
し意外にも、合成ペプチドを用いた結合部位のマッピング解析で、HD8 抗体は多型に富む
領域を認識していることが判明した。さらに詳細に認識部位をペプチド解析した結果、HD8
抗体は、多型を有する領域の中でもほとんどの多型で保存されているアミノ酸を認識して
いることが判明した。さらに、HD8の認識部位のペプチドを各 MHC クラス II で作製し解
析した結果、HLA-DR の 99.2％、HLA-DP の 100％、HLA-DQ の 66％を認識しうることが
判明し、HD8抗体の広い認識性が確認でき、多型克服のストラテジーが示された。 
HD8抗体の薬理効果に関しては、IgG1体において in vitroで強力な抗体依存性細胞性細胞
 傷害活性（ADCC）・補体依存性細胞傷害活性（CDC）を有すること、in vivoにおいてヒト
Bリンパ腫の担ガンマウスにおいて延命効果を示すことから、医薬品としての高い可能性が
示唆された。しかしながら、HD8のヒト IgG1及び IgG2体をサルに投与した際、強いアナ
フィラキシー様の毒性を示した。このアナフィラキシー様反応はインフュージョン反応と
呼ばれる免疫反応のひとつであり、抗体医薬品の投与の際に引き起こされる副作用として
知られている。この HD8 抗体のインフュージョン反応は、ADCC・CDC 能が強い IgG1 の
みでなく、CDC のみが強い IgG2 においても発現したことから、CDC が原因であることが
予測できる。実際に、ラットを用いて新規に構築したインフュージョン反応モデルを用い
たコブラ毒素による補体除去実験において、HD8-IgG1抗体のインフュージョン反応が大幅
に軽減され、CDCが原因である可能性が強く示唆された。 
そこで、毒性を回避し、且つ薬理作用を保持した抗体を作製するため、CDC を低減し
ADCCを保持した抗体の作製を試みた。抗体の Fc領域と Fc受容体の立体構造等を基に Fc
領域の改変を行い、331 番目プロリンのセリン置換により CDCが低減されることが確認さ
れた。さらには、322番目リジンのアラニン置換の追加により、in vitroにおいては CDC能
が全く検出されず、ADCC は若干の低減は認められたものの十分に保持されていた。ラッ
トインフュージョン反応モデルにおいても、二変異抗体はそのインフュージョン毒性の発
現を大幅に軽減した。また、サルに投与した場合では、インフュージョン反応は全く発現
しなかった。薬効に関しては、マウスを用いたヒトリンパ腫担ガンモデルにおいて抗体投
与による延命効果が観察され、薬効の保持も確認できた。 
 
（３）以上の結果、本研究により、Fc領域に 2変異を導入した HD8抗体は抗腫瘍効果を保
持しつつ毒性を大幅に軽減し、医薬品としての高い可能性をもつことが明らかとなった。
また、HLA-DR抗体のインフュージョン反応の主要な原因が CDCであることを明らかにし、
この 2変異が CDCを原因とするインフュージョン反応の軽減法として有効であることを示
すことが出来た。 
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 1
ABBREVIATIONS 
 
Ab, antibody 
Ag, antigen 
ADCC, antibody-dependent cellular cytotoxicity 
CDC, complement-dependent cytotoxicity 
CVF, cobra venom factor 
DDS, drug delivery system 
DMEM, Dulbecco’s modified Eagle’s medium 
DTT, dithiothreitol 
EDTA, ethylene-diamine-tetra-acetic acid 
ELISA, enzyme-linked immunosorbent assay 
E/T ratio, effector to target ratio 
Fab, antigen-binding fragment 
FACS, fluorescence-activated cell sorter 
Fc, constant region fragment 
FCS, fetal calf serum 
FITC, fluorescein isothiocyanate 
 2
HLA, human leukocyte antigen 
HLA-DR, human leukocyte antigen-DR 
Ig, immunoglobulin 
IMDM, Iscove’s modified Dulbecco’s medium 
i.p., intraperitoneal 
IU, international unit 
i.v., intravenous 
KD, affinity constant 
kDa, kilodalton 
mAb, monoclonal antibody 
MFI, mean fluorescence intensity 
mg, milligram 
MHC, major histocompatibility complex 
MLR, mixed leukocyte reaction 
mRNA, messenger ribonucleic acid (RNA) 
µg, microgram 
µL, microliter 
n, number 
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ND, not determined 
NK cell, natural killer cell 
p, probability 
PAGE, polyacrylamide gel electrophoresis 
PBMC, peripheral blood mononuclear cell 
PBS, phosphate buffer saline 
PE, phycoerythrin 
RACE, rapid amplification of cDNA end 
RT-PCR, reverse transcriptase polymerase chain reaction 
s.c., subcutaneous 
scid, sever combined immunodeficiency 
SD, standard deviation 
SDS, sodium dodecyl sulfate 
SEM, standard error of the mean 
TNF, tumor necrosis factor 
TRAIL, tumor necrosis factor (TNF)-related apoptosis inducing ligand 
v/v, volume to volume ratio (%) 
wk, week 
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GENERAL INTRODUCTION 
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Antibody for therapeutic use 
Antibody can bind to a wide variety of potential targets and have been envisioned 
as therapeutic targeting vehicles for a century (1, 2).  The initial use of antibody as 
therapeutic agents is polyclonal antisera, but in many cases they were proved unsuitable 
because of their heterogeneity.  Monoclonal antibodies (mAbs), which were first 
demonstrated by Kohler and Milstein (3), have made us possible to create antibodies 
with requisite pharmaceutical properties.  MAb is capable of binding to a specific 
antigen with remarkable specificity, which property can be refined so that mAbs and 
their derivatives could be used in various therapies. 
The first indication that mAbs might have significant therapeutic potential came in 
1982 when an individual with lymphoma, Philip Karr, showed a complete response to a 
brief treatment with a ‘tailor-made’ mouse anti-idiotype mAb (4).  This notable success 
elicited academic and commercial interest toward antibody researches and investments.  
Nevertheless, the facts that many trials against cancer disclosed lack of efficacy, and a 
lot of pharmaceutical problems of mAbs (too expensive to produce, needed specialist 
expertise to administer, and often associated with considerable toxicity) waned the 
enthusiasms of antibodies in the end of 1980s.  Going through the early experiences 
involving disappointments, it was found that newly-developed antibody technologies 
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enabled to provide eight mAbs for clinical use which had been approved by US Food 
and Drug Administration (FDA) in the late 1990s, and about a hundred of mAbs are 
currently in are currently in clinical trials. 
 
Structure and function of antibody 
Antibodies are immunoglobulins (Ig) produced by B lymphocytes in response to 
the antigenic stimuli (Figure A).  Most immunoglobulins consist of two light and two 
heavy chains that are composed of two different domains (Figure B).  The Fab 
domains serve as the antigen-binding sites, which are composed of variable regions of 
heavy and light chains containing hypervariable regions.  The Fc domains determine 
the effector functions of antibodies, which depend on interactions with Fc receptors and 
complement.  Antibody-dependent cellular cytotoxicity (ADCC) is mediated by 
neutrophils, mononuclear phagocytes, natural killer cells, some T cells and eosinophils, 
which possess a variety of Fc receptors.  Complement-dependent cytotoxicity (CDC) 
is elicited by the cascade of complement components that exist in blood plasma.  The 
effector functions can be customized by selection of Ig subclasses (Table A) and 
modification of the Fc domains.  For example, human IgG1 is known to trigger both 
ADCC and CDC as the potent mediators of cell lyses. 
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            IgM       (Janeway, Immunobiology Fifth edition, 2001) 
 
Figure A. Human immunoglobulins 
 
 
 
 
 
 
 
 
 
 
 
Figure B. Structure of immunoglobulin 
Fc domain 
Fab domain 
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Table A. Immune effector functions of human immunoglobulin isotypes 
 
Antibody ADCC CDC 
IgG1 
IgG2 
IgG3 
IgG4 
IgM 
+++ 
+ 
+++ 
+ 
− 
++ 
+ 
++ 
− 
+++ 
 
Cancer Immunotherapy 
MAbs and their derivatives possess a lot of characteristics that are useful for 
cancer immunotherapy as follows; 
(A) Antibodies with certain Fc domains possess ADCC and/or CDC that act as 
anti-tumor agents through lysing target cells.  ADCC is reported to play an important 
role in tumoricidal activity in antibody therapies using anti-CD20 mAb and breast 
cancers by anti-Her2/neu mAb (5, 6).  The intensity of ADCC and/or CDC can be 
modified by changing the Fc structures.  Some recent researches revealed the critical 
amino acids that affect ADCC and/or CDC by the tertiary structural analyses of Fc / Fc 
receptor complex and the mutagenesis study of Fc region (7, 8).  In addition, Ig-linked 
sugar structure has also been reported to affect ADCC (9). 
(B) In some combinations of antibodies and antigens, the bindings of the 
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antibodies on their antigens themselves induce target cell death.  For example, the cells, 
expressing tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) 
receptor (TRAIL-R), induces programmed cell death (apoptosis) by its antibodies with 
agonistic property that act like its ligand TRAIL (10). 
(C) Drug delivery system (DDS) has been known to be effective for cancer 
immunotherapy (11).  For example, calicheamicin-conjugated anti-human CD33 
antibody (Gemtuzumab Ozogamicin) acts on relapsed or refractory acute myeloid 
leukemia cells by releasing toxins from internalized antibodies (12).  
Radioisotope-labeled antibodies are proved to be effective on several cancers, for 
example, anti-CD20 antibodies (131I-Tositumomab and 90Y-ibritumomab tiuxetan) on 
rituximab-resistant B cell malignancies (13). 
(D) Furthermore, many recombinant antibody-based molecules prepared by 
antibody engineering techniques have been proposed and provided a wide range of 
strategies to develop therapeutic antibody (14).  For example, antibody-based small 
molecules are reported to possess better kinetics of distribution and tissue penetration 
properties than the full-size antibodies. 
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The purpose of this study 
In this dissertation, a new anti-human leukocyte antigen-DR (HLA-DR) antibody 
with fully-human IgG structure is reported as a new possible therapeutic agent against B 
cell malignancies.  HLA-DR has been known to be highly expressed on B cell 
lymphomas and leukemias and has been believed to be a good target of immunotherapy 
for decades, but there has been no anti-HLA-DR antibody for clinical use until now (15).  
Although the exact reasons of the failures of anti-HLA-DR antibodies are still unknown 
yet, it seems to be possible to overcome the difficulties by combining a variety of 
antibody engineering technologies. 
In Chapter I, the new antibody, developed in the present research, is characterized 
from the pharmacological viewpoints, especially its binding characteristics of the 
recognition of polymorphic HLA-DR antigens.  HLA-DR is known to possess 500 
alleles and still increasing, and its polymorphism might have limited the patients 
recognized by anti-HLA-DR antibodies.  The newly developed anti-HLA-DR antibody 
was revealed to have a wide binding property by immunoblot technique that could 
recognize not only HLA-DR alleles but also other MHC class II alleles. 
In Chapter II, the modification of the antibody by genetic engineering technique 
is reported in order to reduce its unexpected toxicity while retaining the efficacy.  The 
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story has started from the unexpected severe toxicities by the antibodies with human 
IgG1 and IgG2 subtypes.  From the hypothesis that the toxicities are caused by one 
component that plays a part of effector functions of antibodies, a new structure of Fc 
domain was created by amino acid substitutions.  The newly designed antibody was 
proved to show the significant reduction of the toxicity in the two models including 
non-human primate studies. 
In brief, a hopeful anti-HLA-DR antibody against B cell malignancies and a new 
option to reduce toxicity of antibodies for clinical use were proposed. 
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CHAPTER I 
 
 
 
A fully-human antibody exhibits pan-HLA-DR recognition 
and high in vitro/vivo efficacy against HLA-DR-positive 
lymphomas 
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Summary 
HD8, a fully human monoclonal antibody specific for human leukocyte 
antigen-DR (HLA-DR), was generated by using the transchromosome mouse that bears 
the human immunoglobulin genes. HD8 could bind to all 13 tested HLA-DR-positive 
cell lines and 35 B-cells from healthy donors. Epitope mapping revealed that while the 
antibody recognizes the most polymorphic region of the HLA-DR-β chain, its critical 
epitope residues are conserved in the major alleles. Indeed, HD8 could recognize 99.2% 
of HLA-DRB alleles. Since its essential epitope residues are also largely conserved in 
HLA-DP and HLA-DQ, HD8 could recognize 100% and 66% of the HLA-DP and 
HLA-DQ alleles tested, respectively. HD8 exerted strong antibody-dependent cellular 
cytotoxicity and complement-dependent cytotoxicity in vitro, and significantly extended 
the life span of immunocompromised mice inoculated with non-Hodgkin lymphoma 
cell lines. The HD8 antibody may be highly useful in HLA-DR-targeted immunotherapy 
as it is likely to evoke similarly strong responses in individuals carrying different 
HLA-DR alleles. 
 16
Introduction 
Many therapeutic antibodies that target B-cell malignancies are currently on the 
market or are being tested in clinical trials (1-4).  An example is the human-mouse 
chimeric anti-CD20 antibody rituximab, which exerts significant anti-tumor effects with 
limited toxicity in non-Hodgkin’s lymphoma and other B-cell malignancies (5, 6). The 
clinical outcomes of rituximab treatment show clearly that antibody-based 
immunotherapy is an effective and safe treatment for lymphoma.  Rituximab is 
believed to exert its anti-tumor effects by several mechanisms, including 
antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity 
(CDC), and death signaling (7, 8).  However, despite the clinical success of rituximab, 
relapses and refractory tumors remain problematic (9).  Consequently, several 
strategies to improve the efficacy of this therapeutic approach have been devised.  One 
of these strategies has led to the radioisotope-conjugated anti-CD20 antibodies, 
ibritumomab (Zevalin) (10) and tositumomab (Bexxar) (11,12).  However, while both 
antibodies augmented the response rate, they have failed to adequately prevent relapses 
or control refractory tumors with CD20-negative cells (9).  Several new anti-CD20 
antibodies, which have recently been generated to exceed the efficacy of rituximab 
(13-16), are all likely to suffer from the same limitations.  Therefore, other approaches 
targeting other molecules expressed on B lymphomas and leukemias have been pursued.  
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These studies have led to an anti-CD22 antibody (17) and an anti-CD19 antibody (18).  
An anti-CD52 antibody (alemtuzumab) has been shown to be successful, but only in 
chronic lymphocytic leukemia (CLL), not in B-cell lymphoma (19). 
Major histocompatibility complex (MHC) class II molecules are non-covalently 
associated heterodimers of two transmembrane glycoproteins.  Human leukocyte 
antigen (HLA)-DR, one of three MHC class II molecules, is expressed on 
antigen-presenting cells, including B lymphocytes, monocytes and dendritic cells, and 
plays pivotal roles in antigen presentation and the induction of antigen-specific immune 
responses.  HLA-DR is also expressed on a wide variety of B-lineage lymphoma and 
leukemia cells, which suggests that it may be a good target for antibody-based 
immunotherapy (20-24).  Many anti-HLA-DR antibodies have been generated, two of 
which have been subjected to clinical trials, namely, humanized 1D10 (Hu1D10) and 
mouse antibody Lym-1.  However, these antibodies were only reactive in a proportion 
of patients with HLA-DR-positive malignancies: Hu1D10 was reported to recognize the 
tumors in only half of the HLA class II-positive hematological malignant patients tested 
(25-27), while Lym-1 failed to recognize some HLA-DR-positive cell lines, 60% of 
B-cell leukemia cells and 20% of the lymphoma patients (22, 28).  These limitations 
arise because the HLA-DR molecule is extremely polymorphic due to its highly 
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variable E chain.  Indeed, more than 500 different HLA-DRB alleles have been 
identified to date (29).  Thus, any immunotherapy targeting HLA-DR will be 
confronted with the problem of target antigen polymorphisms. 
In this chapter, we report the generation of HD8, a novel fully-human antibody 
against the HLA-DR that reacts widely with human malignancies of B-cell lineage and 
recognizes amino acid residues that are largely conserved in the vast majority of 
HLA-DR, HLA-DP and HLA-DQ alleles.  We also show here that HD8 has strong in 
vivo and in vitro tumoricidal activities. 
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Materials and methods 
Reagents 
Phycoerythrin (PE)-conjugated anti-CD20 and fluoroscein-5-isothiocyanate 
(FITC)-conjugated anti-HLA-DR (L243) antibodies were purchased from BD 
Biosciences (San Jose, CA).  The anti-CD20 human-mouse chimeric antibody 
rituximab was purchased from Zenyaku Kogyo (Tokyo, Japan).  Serum-derived human 
IgG was purchased from SIGMA (MO). 
 
Cell lines 
The following 14 cell lines were obtained from the American Type Culture 
Collection (ATCC): ARH77 (CRL-1621), Daudi (CCL-213), HS-Sultan (CRL-1484), 
IM-9 (CCL-159), Jurkat (TIB-152), MC/CAR (CRL-8083), Namalwa (CRL-1432), 
Ramos (CRL-1596), Raji (CCL-86), RL (CRL-2261), RPMI-1788 (CCL-156), 
RPMI-8226 (CCL-155), SKW6.4 (TIB-215), WIL2/S (CRL-8885) and SP2/O-Ag14 
(CRL-1581).  Granta-519 was purchased from German Collection of Microorganisms 
and Cell Cultures (ACC-342).  HLA-DR-positive L929 cells were generated by 
transfecting L929 cells (ATCC CCL-1) with the HLA-DR genes 
DRA*0101/DRB1*15011. 
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Selection of the HD8-producing hybridoma 
To obtain the HD8-producing hybridoma, KM mice (KM mouse) were immunized 
with HLA-DR-transfected L929 cells.  KM mice were generated by the 
transchromosomal technique and produce fully human antibodies upon immunization 
(30).  The spleen cells from the immunized mice were fused with the mouse myeloma 
cell line SP2/O-Ag14 and more than 100 hybridomas were screened for their ability to 
bind to several HLA-DR-positive cell lines.  One hybridoma that produces the 
antibody HD8 (human IgG2, kappa) was selected as it produced a widely-reactive 
anti-HLA-DR antibody. 
 
Preparation of antibodies 
The hybridomas producing the anti-HLA-DR mouse antibodies L243 (ATCC 
HB-55) and Lym-1 (ATCC HB-8612) were transplanted into nude mice intraperitoneally.  
The antibodies produced in the murine ascites were then purified by using protein A 
(Amersham Biosciences, Piscataway, NJ).  The hybridoma producing HD8 was 
conditioned to D-MEM medium containing fetal calf serum (FCS) with low-IgG 
concentrations (Hyclone, South Logan, UT) and the IgG was prepared from the 
hybridoma-cultured media by using protein A. 
To prepare recombinant antibodies, the heavy and light chain mRNAs from the HD8 
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hybridoma were cloned into pGEM-T Easy Vector (Promega, Madison, WI).  The 
antibody variable regions were genetically transferred into the N5KG1-Val Lark vector 
(Biogen IDEC, Cambridge, MA), which has a puromycin resistance gene.  The 
antibodies were expressed in Chinese hamster ovary cells and purified from the culture 
supernatant by using protein A.  The HD8, L243, Lym-1 and serum-derived human 
IgG antibodies were labeled with Alexa488 by using the Alexa Flour 488 antibody 
labeling kit according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). 
 
Reactivity of antibodies with various HLA-DR-positive cells, as determined by flow 
cytometry 
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were 
prepared by the density centrifugation separation method using Ficoll-Paque PLUS 
(Amersham).  The purified PBMCs and the cell lines (2×105 cells each) were then 
incubated for 10 minutes on ice with 1 mg/mL of purified human IgG from sera 
(SIGMA) to block the Fc receptors.  After centrifugation and resuspension in fresh 
medium, the cells were incubated with fluorescence-labeled antibodies at concentrations 
of 0.1, 1 or 10 µg/mL for 30 minutes on ice.  After washing three times with staining 
buffer (1% FCS, 1 mM EDTA in PBS), the cells were suspended in staining buffer 
containing propidium iodide (PI) and the PI-negative cells were analyzed by flow 
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cytometry (FACS, BD Biosciences).  The mean FL-1 fluorescence intensity of each 
sample was calculated by the CellQuest software (BD Biosciences). 
 
Reactivity of HD8 with HLA-DR protein, as determined by immunoblot analysis 
HLA-DR protein was isolated from the membrane fraction of lymphoma cell line 
SKW6.4 (ATCC TIB-215) by affinity chromatography using the originally derived 
anti-HLA-DR D chain mouse antibody.  The affinity-purified protein was subjected to 
electrophoresis in two 4%-20% gradient SDS-PAGE gels in non-reducing conditions.  
One gel was subjected to silver staining, and the two major protein bands detected were 
determined by N-terminal peptide sequencing to be the D and E chains of the HLA-DR 
molecules.  The other SDS-PAGE gel was transferred to a polyvinylidene fluoride 
membrane (Hybond, Amersham), which was then incubated overnight at 4°C with 10% 
blocking reagent (Block Ace: Dainippon Pharmaceutical, Japan) followed by washing 
with TBS containing 0.1% Tween 20 (t-TBS).  The membrane was then probed with 1 
µg/mL HD8 for 1 h at room temperature, washed three times with t-TBS, and incubated 
with horseradish peroxidase-conjugated rabbit anti-human antibody (Biosource, CA) for 
1 h at room temperature.  The membrane was subsequently washed and reacted with a 
chemiluminescent reagent (ECL, Amersham) according to the manufacturer’s 
instructions.  The silver-stained gel and the chemiluminescent membrane were 
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measured by an image analyzer (LAS2000, FujiFilm, Japan). 
 
Epitope analysis by peptide spot assays 
A total of 94 13-mer peptides that span the entire extracellular domain of the 
HLA-DR E chain allele DRB1*15011 and overlap by 11 amino acid residues were 
synthesized and placed on cellulose membranes (Jerini AG, Berlin, Germany) (31).  To 
precisely map the HD8 epitope, peptides in which each consecutive residue of the 
DRB1*15011 sequence 61-WNSQKDILEQARA-73 was substituted with alanine were 
synthesized.  The HD8 epitope homologues in various HLA-DR, DP, and DQ E alleles 
were also synthesized.  The sequence information of the various HLA-DR/DP/DQ 
alleles was obtained from the ImMunoGeneTics HLA Database (European 
Bioinformatics Institute, European Molecular Biology Laboratory) (29).  The peptides 
were engaged in immunoblot analysis with HD8.  The chemiluminescent intensity on 
each dot was then measured and analyzed by the appropriate software. 
 
Epitope analysis by competition with epitope peptide 
The HD8 epitope peptide (61-WNSQKDILEQARA-73 of DRB1*15011) was 
prepared in PBS (-) solution.  Raji cells (2×105 cells) were incubated for 10 minutes on 
ice with 1 mg/mL IgG purified from human sera (SIGMA) to block the Fc receptors.  
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After centrifugation and resuspension in staining buffer, the cells were incubated with 1 
µg/mL Alexa488-labeled HD8 antibody in the presence of the peptide at final 
concentrations ranging from 10 to 1000 µg/mL for 30 minutes on ice.  After washing 
three times with staining buffer, the cells were suspended in staining buffer containing 
PI and analyzed by flow cytometry.  The mean fluorescence intensity was calculated 
by the CellQuest software. 
 
Cytotoxicity assays 
For antibody-dependent cellular cytotoxicity (ADCC) assay, PBMC effectors were 
prepared from healthy volunteers by density centrifugation and suspended in complete 
medium at a concentration of 4×105 cells/mL (4× effector solution for ADCC).  For 
complement-dependent cytotoxicity (CDC) assay, human complement sera (SIGMA) 
were diluted to 20% with complete medium (4× effector solution for CDC).  To label 
the target cells, 106 Raji cells were incubated with 100 µCi of sodium chromium 
containing 51Cr (PerkinElmer Japan) in a total volume of 65 µL FCS-containing PBS (-).  
After a 1-hour incubation at 37°C, the labeled target cells were washed three times to 
remove free 51Cr and 2×103 cells/50 µL were assayed in round-bottom microtiter plates 
(BD Biosciences) with 100 µL  of each antibody (2× antibody solution) at various 
concentrations in complete media.  The 4× effector solutions (50 µL) were then added 
 25
to each well.  All samples were plated in triplicates.  For the ADCC assay, the plates 
were briefly centrifuged and incubated at 37°C for 4 hours.  For the CDC assay, the 
plates were incubated at 37°C for 2 hours.  Tumor cell lysis was measured by 
determining the amount of 51Cr released into the supernatant.  Thus, after the 
incubation, the plates were centrifuged and the supernatants from each well were 
transferred into plates containing scintillator (Lumaplate-96, Packard Bioscience, 
PerkinElmer).  The plates were dried, and counted by a scintillation counter (Top 
Count, Packard Bioscience, PerkinElmer).  The percent specific lysis was determined 
by the following equation: [(E - S)/(M - S)] × 100, where E is counts per minute for 
sample, S is the average spontaneous release in the sample with target cells only, and M 
is the average maximal release in the sample containing target cells lysed with 50 µL of 
1% Triton X-100 detergent. 
 
Mouse lymphoma-xenograft model 
Female scid mice (C.B-17/Icr-scid/scid Jcl, CLEA Japan, Tokyo, Japan) and 
NOD/scid mice (NOD/Shi-scid Jic, CLEA) were housed in autoclaved plastic cages, 
and were maintained in an air-conditioned, specific pathogen-free animal room at a 
temperature of 19-25°C and a relative humidity of 35-75%.  The 12 h lighting cycle 
began with lights on at 8 a.m.  The mice were given sterilized commercial rodent chow 
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and water ad libitum.  All experiments in this study were approved by the Institutional 
Animal Care and Use Committee in our laboratory. 
For the intravenous lymphoma-xenografted model, 6- to 8-week-old scid and 
NOD/scid mice were pretreated with 0.1 mg of anti-asialo GM-1 antisera (Wako Pure 
Chemical Industries, Osaka, Japan) one day (day -1) before 5×106 Raji lymphoma cells 
(ATCC CCL-86) were inoculated intravenously (day 0).  On day 5, various doses of 
HD8 or the anti-CD20 chimeric antibody rituximab were injected intravenously, and the 
survival of mice was monitored daily.  The statistical significance of differences in the 
survival curves was assessed by log-rank test. 
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Results 
Binding spectrum of the novel pan-HLA-DR antibody HD8 
The HD8 antibody against HLA-DR was generated by immunizing KM mice, 
which produce fully human immunoglobulins (30), with HLA-DR-transfected L929 
cells.  Hybridomas derived from the splenocytes of these mice were screened for 
reactivity with various lymphoma cell lines, and finally HD8 was selected by a wide 
reactivity to HLA-DR-positive cells.  The data for HD8 are shown in Table 1-1.  The 
HD8 antibody recognized all HLA-DR-positive 13 lines, mostly strongly (11/13, 85%).  
In contrast, the E chain-specific antibody Lym-1 was much less reactive, since it only 
reacted with seven of 13 cell lines (only one was recognized strongly).  Significantly, 
HD8 recognized HLA-DR-negative plasmacytoma cell line RPMI-8226.  As expected, 
none of the antibodies recognized the HLA-DR-negative Jurkat cell line.  Furthermore, 
HD8 recognized B-cell population of the PBMCs from all 35 human volunteers that we 
tested.  Thus, it appears that HD8 is a widely reactive pan-HLA-DR antibody. 
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Table 1-1.  Reactivity of HD8 with various lymphoma cell lines 
Cell Line Tumor Type 
 HLA-DR† 
expression 
 Reactivity‡ 
Lym1 HD8 
ARH77 Plasma cell leukemia +++ ++ +++ 
Daudi Burkitt's lymphoma +++ + +++ 
Granta519 B-cell non-Hodgkin +++ + +++ 
IM-9 B lymphoblast +++ + +++ 
MC/CAR Plasmacytoma +++ + +++ 
Raji Burkitt's lymphoma +++ +++ +++ 
RPMI1788 B lymphoblast +++ ++ +++ 
HS-Sultan Burkitt's lymphoma +++ − +++ 
Namalwa Burkitt's lymphoma ++ − +++ 
Ramos Burkitt's lymphoma +++ − +++ 
RL B-cell non-Hodgkin +++ − +++ 
SKW6.4 
B-cell lymphocyte (EBV 
transformed) 
++ − ++ 
WIL2/S B lymphoblast ++ − ++ 
     
RPMI8226 Plasmacytoma − − + 
Jurkat T-cell leukemia − − − 
Cells were stained with Alexa488-labeled antibodies HD8 and Lym-1 after blocking 
with non-specific human IgG, and then the mean fluorescence intensity of FL-1 
generated by the PI-negative live cells was measured by flow cytometry.  
Alexa488-labeled non-specific human IgG was used as a negative control.  
†Expression level of HLA-DR on each cell line was confirmed by staining with 
Alexa488-labeled L243.  ‡The relative intensity indices for each antibody are defined 
as follows: ‘−’, no staining; ‘+’, weak staining; ‘++’, intermediate staining; ‘+++', 
strong staining. 
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Epitope analysis of HD8 
To determine whether HD8 binds to the D or E chain of HLA-DR, the purified 
HLA-DR protein from the HLA-DR-positive B-lymphoblastoid cell line SKW6.4 was 
subjected to immunoblot analysis using the HD8 antibody.  SDS-PAGE of the protein 
in non-reducing conditions allowed each HLA-DR protein chain to be detected 
separately.  HD8 recognized the lower band of HLA-DR protein (Figure 1-1a), which 
was confirmed by N-terminal peptide sequencing to be the HLA-DR E chain. 
To identify the HLA-DRB epitope that is recognized by HD8, we synthesized 94 
13-mer peptides that span the entire extracellular domain (199 amino acids) of the 
HLA-DR E chain allele DRB1*15011 (AAK51524.1, GenBank) and overlap by 11 
amino acids.  The peptides were blotted onto cellulose membranes and the ability of 
HD8 to bind to each was tested.  HD8 reacted strongly with peptide numbers 31-33, 
which span amino acids 61-73, 63-75 and 65-77, respectively (Figure 1-1b).  We then 
confirmed that these peptides represent the HD8-binding epitope by determining 
whether free #31 peptide (which has the sequence 61-WNSQKDILEQARA-73) could 
compete with HD8 for binding to the HLA-DR-expressing Raji cell line.  Indeed, the 
#31 peptide significantly inhibited the binding of HD8 to Raji cells in contrast to no 
effect on the binding of anti-HLA-DR D chain antibody L243 (Figure 1-1c).  Thus, the 
61-WNSQKDILEQARA-73 sequence contains the HD8-binding epitope.  This epitope 
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is located on the D helix of the HLA-DR E chain, which is part of the HLA-DR groove 
bound by peptide antigen (32, 33).  Analysis of the IMGT/HLA database, which 
contains the sequences of all known HLA-DRB alleles (29), revealed that while the 
HD8 epitope contains highly polymorphic sequences, it also bears several amino acid 
residues that are largely conserved in HLA-DRB alleles. 
To clarify how HD8 recognizes this highly polymorphic region of the HLA-DR E 
chain, we identified the critical residues in the 61-WNSQKDILEQARA-73 epitope by 
substituting each consecutive residue with alanine.  As shown in Table 1-2, 
substitution of residues 61-64, 67, 70, 71, or 73 had no effect on HD8 reactivity, 
whereas substitution of residues 65, 66, 68, 69 or 72 abrogated HD8 reactivity.  All of 
the latter residues are the mostly conserved residues mentioned above. 
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Figure 1-1 (a).  Delineation of the HD8 epitope on HLA-DR 
HD8 recognizes the E chain of HLA-DR protein.  Affinity-purified HLA-DR protein 
from SKW6.4 cells was subjected twice to SDS-PAGE in non-reducing conditions.  
One gel was silver stained (left) while the other was subjected to immunoblot blot 
analysis with HD8 (right).  The two HLA-DR protein bands detected by silver stain 
were determined by N-terminal protein sequencing to be the D (upper) and E (lower) 
chains of the HLA-DR protein. 
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Figure 1-1 (b).  Delineation of the HD8 epitope on HLA-DR 
Mapping of the HLA-DR epitope recognized by HD8.  94 13-mer peptides spanning 
the entire extracellular domain (199 residues) of the HLA-DR E chain allele 
DRB1*15011 were spot-synthesized onto a cellulose membrane.  The peptides 
overlapped with their direct neighbors by 11 residues.  The membrane was subjected to 
immunoblot analysis with HD8 and the relative chemiluminescence intensities are 
shown.  The sequences of the #31-#33 peptides that are strongly recognized by HD8 
are WNSQKDILEQARA, SQKDILEQARAAV and KDILEQARAAVDT, respectively. 
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Figure 1-1 (c).  Delineation of the HD8 epitope on HLA-DR 
Peptide #31 (61-73) competes with HD8 for binding to the Raji lymphoma cell line.  
2×105 Raji cells were incubated with Alexa488-labeled HD8 (black bars) or L243 
(white bars) antibody and various concentrations (1000, 100, 10 and 0 µg/mL) of 
peptide #31.  The mean fluorescence intensity (MFI) of FL-1 was analyzed by flow 
cytometry, and the ratios relative to the MFIs obtained without peptides are shown. 
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Table 1-2.  Reactivity of HD8 with alanine-substituted peptides 
Peptide 
No. 
61 
W 
62 
N 
63 
S 
64 
Q 
65 
K 
66 
D 
67 
I 
68 
L 
69 
E 
70 
Q 
71 
A 
72 
R 
73 
A 
 SCORE† 
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G 
++++ 
++++ 
++++ 
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− 
− 
++++ 
− 
− 
++++ 
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− 
+++ 
Each consecutive residue in the #31 (61-73) peptide was substituted with alanine and 
the resulting 13 peptides were spot-synthesized on cellulose membranes and subjected 
to immunoblot analysis with the HD8 antibody.  '-' indicates the same amino acid as 
the epitope peptide #31, WNSQKDILEQARA.  †The relative intensity indices are 
defined as follows: '++++', very strong; '+++', strong; '++', intermediate; '+', weak; '−', 
no signal. 
 35
In vitro binding of HD8 to the spectrum of different MHC class II alleles 
We then tested the reactivity of HD8 with various MHC class II molecules by 
synthesizing 25, 9, and 7 13-mer peptides that bear the 61-73-homologue sequences of 
HLA-DR, HLA-DP, and HLA-DQ E chain alleles, respectively.   These peptides 
together represent the homologue sequences of nearly all alleles apart from a few DR 
and DP alleles.  These peptides were subjected to immunoblot analyses using the HD8 
antibody.  The sequences of the peptides, the HD8 reactivity scores, and the number of 
different alleles represented by each peptide sequence are shown in Table 1-3.  This 
analysis revealed that HD8 reacted with 21 of 25 HLA-DR peptides, all of which were 
frequently used sequences.  This means that HD8 can recognize 511 of 515 different 
HLA-DR E alleles (99.2%).  HD8 also recognized all HLA-DP peptides and 5/7 
HLA-DQ peptides (which represent 66% of all HLA-DQ alleles) (Table 1-3).  
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Table 1-3.  Reactivity of HD8 with peptides bearing the 61-73-homologue 
sequences of HLA-DR, HLA-DP and HLA-DQ E chain alleles 
MHC 
Type 
Peptide 
No. 
61 
W 
62 
N 
63 
S 
64 
Q 
65 
K 
66 
D 
67 
I 
68 
L 
69 
E 
70 
Q 
71 
A 
72 
R 
73 
A 
SCORE† 
No. of 
 Alleles‡ 
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19 
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21 
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26 
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4 
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Table 1-3 (Continued).  Reactivity of HD8 with peptides bearing the 
61-73-homologue sequences of HLA-DR, HLA-DP and HLA-DQ E chain alleles 
DP 
31 - - - - - - F - - E E - - +++ 1 
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33 
17 
7 
5 
4 
3 
1 
Cellulose membranes bearing 25, nine, and seven 13-mer peptides that represent most 
of the 61-73-homologue sequences of human leukocyte antigen (HLA)-DR, HLA-DP 
and HLA-DQ alleles, respectively, were generated and subjected to immunoblot 
analysis with HD8.  Shadowed rows indicate the critical residues for HD8 binding 
determined by alanine substitution on Table 1-2.  '-' indicates the same amino acid as 
the epitope peptide #31, WNSQKDILEQARA.  †The relative intensity indices are 
defined as follows: '++++', very strong; '+++', strong; '++', intermediate; '+', weak; '−', 
no signal.  ‡The number of alleles represented by each peptide, as determined by 
analysis of a public database, is shown to the right. 
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Ability of HD8 to induce in vitro cytotoxicity  
To determine whether the HD8 antibody is tumoricidal, we first examined its ability 
to induce ADCC and CDC against Raji in vitro (Figure 1-2).  To maximize the 
capacity of HD8 to induce ADCC and CDC by human effectors, IgG1-type HD8 was 
constructed from the original IgG2-type of HD8 by subclass conversion.  The 
IgG1-type HD8 produced strong ADCC and CDC, both of which are stronger than 
IgG2-type that produced weak ADCC and medium CDC.  In contrast, rituximab 
(IgG1) induced even weaker ADCC than IgG1-type HD8 and could not generate CDC 
against Raji.  The negative control antibody failed to induce either ADCC or CDC. 
 
Anti-tumor activity of HD8 in lymphoma-xenografted murine models 
To address the in vivo anti-tumor efficacy of HD8, scid mice were inoculated with 
either the lymphoma cell line Raji or the lymphoblastoid cell line MC/CAR and injected 
five days later with 5 or 50 µg/kg of the original IgG2-type HD8, rituximab, or control 
human IgG (Figure 1-3).  Scid mice that were xenografted with Raji and MC/CAR and 
treated with control IgG died within 42 and 70 days of transplantation, respectively.  
Rituximab significantly prolonged the life spans of Raji-bearing and MC/CAR-bearing 
mice at doses of 5 and/or 50 µg/kg (p<0.05).  HD8 treatment at both 5 and 50 µg/kg 
also significantly prolonged the life spans of both models (p<0.001); indeed, 50% and 
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100% of the Raji-bearing and MC/CAR-bearing animals were long-term survivors, 
respectively. 
To determine whether the host effector function contributes to HD8 efficacy, we 
transplanted NOD/scid mice with Raji and treated them with 50 or 500 µg/kg HD8 on 5 
days later.  NOD/scid mice are known to possess less NK and complement activities 
than scid mice (34).  HD8 treatment significantly prolonged the life spans of the mice 
compared to control antibody-treated mice (p<0.01 and p<0.001 for 50 and 500 µg/kg 
HD8, respectively).  However, a higher dose of HD8 was needed to achieve a similar 
outcome in NOD/scid models relative to that observed in the scid models (Figure 1-3, 
compare top left and middle panels). 
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Figure 1-2.  Abilities of IgG1- and IgG2-type HD8s to induce ADCC and CDC 
51Cr-labeled Raji cells were incubated with increasing concentrations of IgG1-type HD8 
(■), original (IgG2-type) HD8 (□), the chimeric mouse-human IgG1 rituximab (●), or 
the control antibody (no symbol, dotted line) together with human effector PBMCs 
(ADCC assay, upper graph) or 5% complement sera (CDC assay, lower graph).  The 
specific lysis ratios were then calculated.  The bars represent the SEMs of triplicates.  
Repeated experiments yielded similar and consistent results.
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Figure 1-3.  Anti-tumor activity of HD8 in lymphoma-xenograft mouse models 
Scid (left and right graphs) and NOD/scid (middle graphs) mice were pretreated with 
anti-asialo GM-1 antisera on day -1, inoculated with Raji (left and middle graphs) or 
MC/CAR (right graphs) lymphoma cells intravenously on day 0, and treated with 5, 50 
or 500 µg/kg of HD8 (top graphs), rituximab (bottom graphs), and control IgG on day 5.  
The asterisks indicate significant differences relative to the survival of control 
IgG-administered mice, as determined by log-rank tests (*p<0.05, **p<0.01, 
***p<0.001). 
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Discussion 
It has been known already for decades that many B-lineage tumor cells express 
HLA-DR (35, 36).  Consequently, this molecule is considered to be an attractive target 
molecule for the treatment of B-cell malignancies.  However, while two anti-HLA-DR 
antibodies (Lym-1 and Hu1D10) have been brought to clinical trial, neither has yet been 
approved for clinical application.  One significant problem suffered by these 
anti-HLA-DR antibodies is the limited spectrum of HLA-DR molecules that they can 
recognize because of the extreme polymorphism of HLA-DR.  The polymorphism of 
HLA-DR is largely due to E chain variability, as several hundred E chain alleles exist.  
Consequently, anti-HLA-DR E chain antibodies like Lym-1 and Hu1D10 react with just 
a proportion of HLA-DR alleles. 
Here, we report the generation of HD8, a novel, fully-human antibody against 
HLA-DR that is largely unaffected by HLA-DR polymorphism.  Surprisingly, HD8 
could react with highly-polymorphic HLA-DR E chain.  Moreover, while its epitope is 
situated very close to the epitopes of Lym-1 and Hu1D10, all of which are located in a 
highly polymorphic region of HLA-DR E chain (26, 28, 37), HD8 could react with 
99.2% of the 515 HLA-DRB alleles tested.  That HD8 could nevertheless react with a 
much wider range of HLA-DR alleles can be explained by the fact that the essential 
residues of the HD8 epitope coincide exactly with residues that are largely conserved 
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among the various HLA-DRB alleles.  Notably, since these residues are also highly 
conserved in HLA-DPB alleles and moderately conserved in HLA-DQB alleles, HD8 
could also recognize 100% and 66% of the HLA-DPB and HLA-DQB alleles, 
respectively.  That HD8 recognizes not only HLA-DR but also the other two MHC 
class II molecules might enhance the cytotoxicity of this antibody, as it would increase 
the absolute amount of antibodies bound to the target cell.  In regard to this, the 
expression levels of some target antigens have been shown to shape anti-tumor effector 
functions (38).  These favorable characteristics of HD8 may broaden its clinical 
potential. 
It is currently difficult to predict the pharmacological efficacy of a given antibody 
on the basis of its binding characteristics, including its epitope location.  However, the 
variables that shape the efficacy of an antibody are gradually being elucidated.  For 
example, Polyak and Deans have reported that heterogeneity in the fine specificity of 
anti-CD20 antibodies is due to marked differences in their ability to induce homotypic 
cellular aggregation and translocation of CD20 to lipid rafts (39).  Similarly, Cragg and 
colleagues reported that anti-CD20 antibodies could be classified into two groups on the 
basis of their ability to segregate CD20 into lipid rafts; notably, this segregating ability 
also correlated with their ability to induce complement-mediated lysis (40).  Whether 
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anti-HLA-DR antibodies can be similarly categorized remains to be determined. 
Our mapping analyses revealed that the essential epitope residues of HD8 are 
residues 65, 66, 68, 69 and 72.  Analysis of the tertiary structure of HLA-DR revealed 
that these residues are located on the outer portion of the D helix which forms the 
antigen-presenting groove together with the HLA-DR D chain (32, 33).  This suggests 
that HD8 could be immunosuppressive when used clinically, as it could interfere with 
the antigen-presenting function of HLA-DR.  However, we found HD8 is not 
particularly immunosuppressive when tested in an allogenic mixed leukocyte reaction 
assay (data not shown), which result may come from its epitope existing on “outer” 
portion of the groove.  How the pharmacological efficacy and immunosuppressive 
capacity of HD8 relate to its epitope location should be studied further. 
How HLA-DR antibodies induce tumor cell cytotoxicity is an important issue to be 
clarified.  Many papers have reported that such antibodies may induce HLA-DR 
signaling including programmed cell death (26, 41-47).  We also observed that HD8 
induced programmed cell death in the same way of other anti-HLA-DR antibodies 
(unpublished data, 2006).  In addition, we found that IgG1-type HD8 induced strong 
ADCC and CDC using human effectors in in vitro assays.  We also showed in vivo 
tumoricidal activity of HD8 by employing three lymphoma-xenograft models.  In all 
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three models, HD8 was considerably more effective in prolonging murine life span than 
rituximab, which difference of two antibodies may attribute to the expression levels of 
the target proteins and the affinities of antibodies to the antigens (data not shown).  We 
also noticed that more HD8 was needed to prolong the lives of NOD/scid 
Raji-xenografted mice compared to the amount needed to exert an equivalent effect in 
scid Raji-xenografted mice.  Since the NOD/scid mouse is known to have less NK and 
complement activities than the scid mouse (34), this observation supports the notion that 
the tumoricidal activity in vivo depends on ADCC and/or CDC, which notion should be 
elucidated further.  Notably, the clinical study of the humanized anti-HLA-DR IgG1 
antibody Hu1D10 has suggested the existence of an additional pharmacological 
mechanism, as some Hu1D10-responsive patients were found to develop anti-tumor 
antibodies (48).  Thus, it is possible that HLA-DR antibodies could somehow provoke 
an immune response against the tumor.  To elucidate how HD8 exerts its tumoricidal 
functions, additional experiments are required. 
There remains a critical issue which subclass of human antibody should be chosen 
for anti-HLA-DR antibody.  Kostney and colleagues reported Hu1D10 antibody with 
IgG1-type (26), whereas Nazy and colleagues reported IgG4-type antibody in 
preclinical study (46).  In our unpublished data (2006), IgG1- and IgG2-types HD8 
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antibody expressed stronger tumoricidal efficacy than IgG4-type HD8 in the 
Raji-xenograft scid mouse model.  Both IgG1- and IgG2-types HD8 possessed both 
strong ADCC and CDC in vitro by using mouse effectors.  In Figure 1-2 using human 
effectors, IgG1-type expressed the strongest ADCC and CDC.  Therefore, we chose 
IgG1-type HD8 as a clinical candidate. 
Besides, side effects of anti-HLA-DR antibodies should be elucidated, as HLA-DR 
is expressed on a wide variety of hematopoietic cells, such as myeloid progenitor cells 
and antigen presenting cells. 
In conclusion, IgG1-type HD8 is promising as a potential immunotherapeutic agent 
against HLA-DR-positive lymphocytic cancers, as its structure is completely human, it 
exerts strong efficacies on in vitro cytotoxicity assays and in vivo xenograft models, as 
well as it shows pan-HLA-DR reactivity. 
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CHAPTER II 
 
 
 
Complement activation plays a key role in antibody-induced 
infusion toxicity in monkeys and rats 
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Summary 
Infusion reactions are a major side effect of the administration of therapeutic 
antibodies and are the result of complex immune reaction.  We report here that 
substitutions of Fc amino acids in the anti-HLA-DR antibody HD8 reduce its ability to 
induce infusion reactions in rats and monkeys.  We first showed that intravenous 
administration of IgG1- and IgG2-subclass HD8 antibodies induces severe infusion 
reactions in monkeys.  These antibodies express strong complement-dependent 
cytotoxicity (CDC), and in vivo depletion of complement in rats by pretreatment with 
cobra venom factor abrogated the lethal infusion reactions generated by HD8-IgG1.  
Thus, the infusion reactions appear to be largely driven by the complement system.  To 
reduce the CDC function of HD8-IgG1, its Fc region was modified by two amino acid 
substitutions at Pro331Ser and Lys322Ala.  The modified antibody was incapable of 
expressing CDC in vitro and did not induce severe infusion reactions in rats and 
monkeys, even at extremely high doses.  The modified antibody retained its 
antibody-dependent cellular cytotoxicity function as well as its anti-tumor activity in a 
tumor-bearing mouse model.  In summary, complement appears to drive infusion 
reactions and modifications that eliminate the CDC activity of an antibody also reduce 
its ability to induce infusion reactions. 
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Introduction 
Infusion reactions are infusion-related side effects that occasionally occur especially 
upon intravenous treatment with antibody-based drugs (e.g. rituximab and trastuzumab) 
(1-3).  Infusion reactions manifest themselves as flu-like or anaphylaxis-like symptoms 
such as chills, asthenia, nausea, headache, rash, and vomiting.  Several immune 
mechanisms have been suggested to be responsible for the induction of infusion 
reactions.  First, the intensity of infusion reactions has been positively correlated with 
the rapid release of large amounts of cytokines, especially inflammatory cytokines. For 
example, the infusion of the anti-CD3 antibody OKT3 induces massive cytokine release 
(4, 5).  Second, several therapeutic antibodies have been suggested to activate the 
complement system, resulting in the production of large amounts of C3a, C4a and C5a 
which can act as anaphylatoxins and induce the release of chemical mediators such as 
histamine and leukotriene (2, 6).  Third, rituximab has also been suggested to induce 
the acute lysis of a large number of tumor cells via antibody-dependent cellular 
cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC); this in turn 
induces an inflammatory reaction, i.e. infusion reaction, known as tumor lysis syndrome 
(7-9).  The infusion reactions can be ameliorated to some extent by administering 
appropriate drugs and decreasing the infusion rate (10).  Nevertheless, the precise 
mechanisms leading to infusion reactions and preventing them remain to be elucidated. 
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HLA-DR has been suggested to be a candidate target for antibody-based therapies 
against hematological malignancies.  It has been shown that while the IgG1-type 
anti-HLA-DR antibody Hu1D10 induces infusion reactions (11-13), the IgG4-type 
anti-HLA-DR antibody 1D09C3 does not (14).  Since IgG4 antibodies do not evoke 
either ADCC or CDC, these observations suggest that the infusion reactions occurred by 
anti-HLA-DR antibodies like Hu1D10 are induced by effector functions such as ADCC 
and/or CDC.  In this chapter, we show that our anti-HLA-DR antibody HD8 (15) also 
induces an infusion reaction, and that this reaction correlates positively with the ability 
of this antibody to induce CDC.  We also show that modifications of critical areas of 
the Fc region of HD8 that decrease the CDC potential of this antibody also reduce the 
risk of infusion reactions while retaining the ability of this antibody to induce ADCC 
against tumor cells. 
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Materials and methods 
Preparation of antibodies 
To obtain hybridomas producing anti-HLA-DR antibodies, KM mice were 
immunized with HLA-DR-transfected L929 cells (American Type Culture Collection 
(ATCC): CCL-1).  KM mice were generated by the transchromosomal technique and 
produce fully human antibodies upon immunization (16).  The spleen cells from the 
immunized mice were then fused with the mouse myeloma cell line SP2/O-Ag14 
(ATCC: CRL-1581) and the hybridoma producing HD8 was selected since it recognizes 
a wide variety of HLA-DR molecules (15). 
To prepare the three recombinant HD8-based antibodies used in this study, the 
heavy and light chains expressed by the HD8 hybridoma were cloned into pGEM-T 
Easy Vector (Promega, Madison, WI) and transferred into the N5KG1-Val Lark vector 
(Biogen IDEC, Cambridge, MA).  This generated the IgG1-type HD8 (HD8-IgG1) 
antibody.  To make the modified IgG1-type HD8 antibodies that show reduced 
complement activation potential, standard point-mutation procedures were used to 
introduce the Pro331Ser alone and Pro331Ser plus Lys322Ala substitutions into the 
IgG1 Fc region of the HD8-IgG1 antibody (the EU numbering system (17) was used).  
The resulting antibodies were designated as HD8-IgG1-Ser331 and 
HD8-IgG1-Ala322Ser331, respectively.  The antibodies were expressed in Chinese 
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hamster ovary cells or HEK293 cells and purified from the culture supernatants by 
using protein A (Amersham Biosciences, Piscataway, NJ).  Flow cytometric analysis 
revealed that these HD8 antibodies reacted to HLA-DR molecules with the same 
binding characteristics as the original antibody (data not shown).  To generate Fab 
fragments from the HD8 antibody, HD8-IgG1 was digested by immobilized papain by 
using a Fab fragment preparation kit (Pierce, Thermo Scientific, Rockford, IL). 
 
Animals 
All rodents were maintained in air-conditioned, specific pathogen-free animal rooms 
with sterilized commercial rodent chow and water ad libitum.  Cynomolgus monkeys 
were maintained in stainless steel cages in an air-conditioned room with commercial 
chow and water ad libitum.  All experiments in this study were approved by the 
institutional animal care and use committee of the test facilities. 
 
In vitro cytotoxicity assays 
For the ADCC assay, PBMCs were prepared from healthy volunteers by density 
centrifugation.  For the CDC assay, human sera (SIGMA, MO) were used.  Target 
Raji tumor cells (ATCC CCL-86) were labeled with 51Cr-sodium chromate 
(PerkinElmer Japan) for 1 hour at 37°C.  For the ADCC assay, the target cells were 
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mixed with the PBMCs and antibodies, and incubated at 37°C for 4 hours.  For the 
CDC assay, the target cells were mixed with human sera and antibodies, and incubated 
at 37°C for 2 hours.  Tumor cell lysis was measured by determining the amount of 51Cr 
released into the supernatant by a scintillation counter.  The percentage of specific lysis 
was determined by the following equation: 100 × (experimental release – spontaneous 
release) / (maximum release – spontaneous release).  To perform the ADCC and CDC 
assays using rat effectors, the procedures described above were followed using PBMCs 
or spleen cells (ADCC assay) and sera (CDC assay) from WKAH rats (Japan SLC, 
Shizuoka, Japan).  All human specimens used were approved by the Institutional 
Ethical Committee of our facility. 
 
Non-human primate study 
Ten 3-7 year-old male cynomolgus monkeys were used in total.  We first examined 
whether HD8 could recognize their CD20-positive PBMCs known to express MHC 
class II antigens by flow cytometric analyses.  All monkeys were strongly recognized 
by HD8 (data not shown).  To evaluate the toxic effects of HD8 and its Fc variants, the 
monkeys were given the antibodies or vehicle (PBS containing 1% monkey serum) 
intravenously by infusion pumps (BSP-99M, Braintree Scientific, Braintree, MA) and 
their behaviors were monitored.  Typical symptoms of infusion reaction are passive 
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behavior, recumbency, pallor, nausea, vomiting, and in more severe cases, hypothermia, 
hyperventilation and occasional death, which are expressed within a few hours.  The 
intensity of these infusion reactions was scored as follows: ‘+++’ as strong (e.g. severe 
hypothermia and hyperventilation with occasional mortality); ‘++’ as intermediate (e.g. 
mild hypothermia and long-term recumbency without mortality); ‘+’ as weak (e.g. 
passive behavior and short-term recumbency); and ‘−’ as no abnormal change. 
 
Rat infusion reaction model 
Various rats were screened by flow cytometry to identify strains which are 
recognized by HD8.  The WKAH rat (Japan SLC) was selected on the basis of the high 
reactivity of its PBMCs with HD8 (data not shown).  Five-week-old male WKAH rats 
were bolus-injected with various antibodies intravenously and their behaviors were 
monitored for 5 hours continuously and daily thereafter.  The infusion reaction 
symptoms were scored as described above.  Seriously injured animals were euthanized.  
To determine whether the infusion reaction correlates with serum complement, the 
WKAH rats were injected intravenously with cobra venom factor (CVF) (18) from Naja 
melanoleuca (US Biological, Swampscott, MA) at 100 µg per animal (about 1 mg/kg) 5 
hours prior to the administration of the HD8 antibodies. 
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In vivo anti-tumor activity on mice 
To generate a lymphoma-xenografted model, 6- to 8-week-old scid mice were 
injected with 0.01 mL anti-asialo GM-1 antisera (Wako Pure Chemical Industries, 
Osaka, Japan) one day before (day -1) the intravenous inoculation of 5×106 Raji cells 
(day 0).  On day 5, the mice were injected intravenously with 500 µg/kg of HD8-IgG1, 
HD8-IgG1-Ala322Ser331 or control antibody and their survival was monitored daily.  
The survival data were analyzed statistically by the log-rank test. 
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Results 
Toxicity of anti-HLA-DR antibodies in cynomolgus monkeys 
The antibody HD8, which we previously reported to recognize a wide range of 
HLA-DR molecules (15), was used to examine its ability to induce infusion reactions in 
cynomolgus monkeys.  All monkeys used in this study were confirmed by flow 
cytometric analysis to react strongly with the HD8 antibody (data not shown).  Two 
monkeys were infused with the vehicle by using infusion pumps while one monkey 
received the IgG1-type antibody HD8-IgG1 and another received the IgG2-type 
antibody HD8-IgG2.  The antibodies were administered initially at 0.003 mg/kg.  At 
hourly intervals, the dose was escalated to 0.03, 0.3, and 1.5 mg/kg.  The behaviors of 
the animals were monitored and scored to provide a measure of the intensity of the 
infusion reaction (Table 2-1).  Neither antibody induced abnormal changes at doses of 
0.003, 0.03 and 0.3 mg/kg, but severe reactions were observed at the 1.5 mg/kg dosing 
of both antibodies.  Indeed, both monkeys died after this dose was delivered.  The 
two control monkeys did not manifest any infusion reaction symptoms. 
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Table 2-1. Ability of anti-HLA-DR antibodies to induce infusion reactions in 
cynomolgus monkeys 
Treatment 
Dose 
(mg/kg) 
Infusion 
Duration 
(minutes) 
n 
Infusion 
reaction score* 
Vehicle − 30 2 − 
HD8-IgG1 0.003 30 1† − 
 0.03 30  − 
 0.3 30  − 
 1.5 15  +++ 
HD8-IgG2 0.003 30 1† − 
 0.03 30  − 
 0.3 30  − 
 1.5 15  +++ 
*The intensity of the infusion reaction was scored on the basis of monkey behavior 
described in Materials and methods.  †The dose of each animal was escalated at hourly 
intervals. 
 
In vitro cytotoxicity assays by human effectors 
Since the infusion reactions of anti-HLA-DR antibodies were shown to be induced 
by IgG1-type (12, 13) and IgG2-type antibodies (Table 2-1), both of which possess 
strong CDC, and not by IgG4 antibody with no CDC (14), we tested whether the 
infusion reactions generated by antibody therapies arise from CDC.  We generated 
 66
recombinant HD8-IgG1 antibodies bearing the Pro331Ser alone and Pro331Ser + 
Lys322Ala substitutions in their Fc regions.  These substitutions were speculated to 
reduce the CDC potential of HD8-IgG1 without affecting its ADCC function (19, 20).  
The locations of amino acids 322 and 331 in the Fc region of IgG1 are indicated in 
Figure 2-1, which shows the tertiary structure of the IgG1 Fc bound to the Fc receptor 
(cited from PDB database No.1E4K) (21, 22).  Residues 322 and 331 do not overlap 
directly with the binding site of the Fc receptor.  To test the effect of the substitutions 
on HD8-IgG1 cytotoxicity activity, HD8-IgG1 and these variants were then subjected to 
in vitro ADCC and CDC assays using human PBMCs and sera, respectively.  While 
HD8-IgG1 evoked both ADCC and CDC, HD8-IgG1-Ser331 generated markedly 
weaker CDC and slightly weaker ADCC, while HD8-IgG1-Ala322Ser331 induced 
weaker ADCC and no CDC at all (Figure 2-2).  Thus, while the antibodies bearing one 
or both of the two amino acid substitutions still evoked some ADCC, their ability to 
induce CDC was decreased or absent in comparison with the original IgG1 antibody. 
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Figure 2-1. Positions of the substituted Fc amino acids in the Fc/Fc receptor 
complex 
The locations in the tertiary structure of human IgG1 Fc of the amino acids that were 
substituted in the modified HD8 antibodies are shown.  Two CH2-CH3 domains of the 
IgG1 Fc region and the FcJRIII (cited from Protein Data Bank, No.1E4K) are shown in 
purple/blue and brown, respectively.  The Lysine322 and Proline331 residues are 
highlighted in yellow. 
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Figure 2-2. Ability of the Fc-variant HD8-IgG1 antibodies to induce ADCC and 
CDC in vitro 
The HD8-IgG1 (○), HD8-IgG1-Ser331 (□), HD8-IgG1-Ala322Ser331 (■), and control 
antibodies (dotted line) were incubated at various doses with 51Cr-labeled Raji target 
cells along with (Left) healthy human PBMCs as effector cells at an E/T ratio of 100 for 
4 hours (ADCC assay), or with (Right) 5% human sera for 2 hours (CDC assay).  The 
specific lysis ratios were then calculated by the formula described in the Materials and 
methods.  The bars represent the SEMs of triplicates.  Repeated experiments yielded 
similar and consistent results. 
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Ability of HD8 Fc variant antibodies to induce infusion reactions in a rat model 
To test the effect of the Fc residue substitutions on the ability of HD8-IgG1 to 
induce infusion reactions, we established a rat infusion reaction model.  Various rodent 
strains were screened to identify strains recognized by HD8-IgG1.  The rat strain 
WKAH was recognized strongly by HD8 (data not shown) and thus this strain served as 
the infusion reaction model. . 
Initially, we examined the ability of HD8-IgG1 and its Fc variants to induce ADCC 
and CDC in vitro by using WKAH rat PBMCs and sera, respectively (Table 2-2).  
HD8-IgG1, HD8-IgG1-Ser331 and HD8-IgG1-Ala322Ser331 all induced  ADCC 
equally well but HD8-IgG1-Ser331 evoked CDC more weakly than HD8-IgG1, while 
HD8-IgG1-Ala322Ser331 did not induce CDC at all.  We then examined the abilities 
of these antibodies to evoke an infusion reaction in the rat model.  Thus, the rats were 
infused intravenously with 1, 3, or 10 mg/ml of antibody by bolus administration, and 
their behavior was monitored and scored to indicate the intensity of the infusion 
reaction (Table 2-2).  Neither the Fab fragment of HD8-IgG1 nor the control IgG 
generated abnormal signs, even at 10 mg/kg.  However, HD8-IgG1 induced severe 
infusion reactions: one of the three rats receiving 1 mg/kg died while all three receiving 
3 mg/kg died.  In contrast, HD8-IgG1-Ser331 induced a weak infusion reaction at 3 
mg/kg and lethal toxicity was not observed, although at 10 mg/kg, it killed three of five 
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rats.  HD8-IgG1-Ala322Ser331 only evoked a weak infusion reaction at both 3 and 10 
mg/kg and lethal toxicity was not observed.  Thus, the severity of the infusion 
reactions followed the order HD8-IgG1 > HD8-IgG1-Ser331 > 
HD8-IgG1-Ala322Ser331 >> Fab fragments and control IgG.  This correlates 
positively with the ability of the antibodies to evoke CDC.  Thus, decreasing the 
ability of the HD8 antibody to evoke CDC also reduces its ability to induce infusion 
reaction in rats. 
To test this notion further, we pretreated WKAH rats with CVF, which is known to 
activate and deplete complement (18).  Thus, four WKAH rats were injected 
intravenously with CVF 5 hours before a lethal dose of HD8-IgG1 (3 mg/kg) was 
administered (Table 2-2).  The administration of CVF itself did not induce any 
abnormal changes.  HD8-IgG1 induced a infusion reaction in the CVF-treated rats 
briefly but all rats returned to normal within 2 hours.  These results strongly suggest 
that complement activation is one of the major causes of the infusion reactions induced 
by the anti-HLA-DR antibody HD8. . 
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Table 2-2. Ability of HD8 antibodies to induce ADCC and CDC in vitro and 
infusion reactions in vivo in the WKAH rat model 
Group Treatment 
Antibody Dose 
(mg/kg) 
Score‡ 
Name ADCC† CDC† 
1 None HD8-IgG1 +++ +++ 1 ++ 
     3 +++ 
2 None HD8-IgG1- +++ + 3 + 
  Ser331   10 ++ 
3 None HD8-IgG1- +++ − 3 + 
  Ala322Ser331   10 + 
4 None HD8-Fab − − 10 − 
5 None Control IgG1 − − 10 − 
6* CVF HD8-IgG1 +++ +++ 3 + 
*Group 6 animals were given CVF (100 µg/rat) 5 hours before a lethal dose of 
HD8-IgG1 (3 mg/kg) was administered.  †The ability of the antibodies to evoke ADCC 
and CDC in vitro when WKAH rat effectors (PBMCs and sera, respectively) were used 
was scored as ‘+++’, ‘++’, ‘+’ and ‘−’.  ‡The intensity of the infusion reaction was 
scored on the basis of rat behavior described in Materials and methods. 
 
Ability of HD8-IgG1-Ala322Ser331 to induce infusion reactions in cynomolgus 
monkeys 
We then examined whether HD8-IgG1-Ala322Ser331 induces infusion toxicity in 
cynomolgus monkeys (Table 2-3).  Three monkeys were given vehicle or 
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HD8-IgG1-Ala322Ser331 at a dose of 50 mg/kg intravenously by 4-hour infusion (12.5 
mg/kg/hour).  Remarkably, no infusion reactions was observed in any of the monkeys 
at all. 
 
Table 2-3. Ability of HD8-IgG1-Ala322Ser331 to induce infusion reactions in 
cynomolgus monkeys 
Antibody 
Dose 
(mg/kg) 
Infusion 
Duration 
(minutes) 
n Score* 
Vehicle − 240 3 − 
HD8-IgG1- 
Ala322Ser331 
50 240 3 − 
*The intensity of the infusion reaction was scored on the basis of monkey behavior 
described in Materials and methods. 
 
In vivo anti-tumor activity of HD8-IgG1-Ala322Ser331 in a mouse xenograft model 
Scid mice were xenografted intravenously with Raji cells, treated intravenously 
with 500 µg/kg HD8-IgG1 or HD8-IgG1-Ala322Ser331 five days later, and monitored 
for their survival (Figure 2-3).  All mice given the control IgG died within 22 days of 
transplantation.  In contrast, HD8-IgG1 and HD8-IgG1-Ala322Ser331 significantly 
prolonged the life spans of these mice (both p<0.001).  While the half lives of the 
HD8-IgG1- and HD8-IgG1-Ala322Ser331-treated mice were 26 days and 30 days, 
respectively, this difference was not statistically significant. 
 73
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3. In vivo anti-tumor activity of HD8-IgG1-Ala322Ser331 
HD8-IgG1-Ala322Ser331 prolongs the survival of lymphoma-xenografted mice.  Scid 
mice were pretreated with anti-asialo GM-1 antisera on day -1, inoculated with Raji 
lymphoma cells intravenously on day 0, and then treated with 50 µg/kg HD8-IgG1 (○), 
HD8-IgG1-Ala322Ser331 (■), or control IgG (dotted line) on day 5.  The asterisks 
indicate significant differences in comparison with control IgG-administered mice, as 
determined by the log-rank test (***p<0.001). 
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Discussion 
Therapeutic antibodies sometimes induce infusion reactions, and they can 
occasionally be life-threatening.  Currently, such reactions are reduced or prevented by 
alterations in clinical practices, for example, by slowing the infusion rate, instituting 
prophylactic treatment with anti-histamine drugs, and treating the symptoms with 
corticosteroids (1).  We show here directly for the first time that severe infusion 
reactions can be avoided by modifying the Fc region of the therapeutic antibody. 
Consistent with what has been observed previously (1, 2, 6), we showed that the 
severity of the infusion reactions generated by the antibodies is associated with the 
activation of the complement system since our prototype IgG1- and IgG2-subclass 
anti-HLA-DR antibodies did not just induce severe infusion reactions in both rats and 
monkeys, they also evoked strong CDC responses when human and rat sera were used 
as the effector source.  This association between infusion reactions and the 
complement system was confirmed when we pretreated rats with CVF, which depletes 
complement, before administering a lethal dose of HD8-IgG1: these rats suffered only a 
mild infusion reaction. 
To reduce this CDC function of the HD8 antibody, we sought to modify its Fc 
region.  We could have chosen to express the antibody as a IgG4-subclass antibody, as 
such antibodies lack both CDC and ADCC functions.  Indeed, Nazy et al. have shown 
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that an anti-HLA-DR antibody of this subclass does not induce infusion toxicity in 
monkeys (14).  However, rituximab has been shown to be effective against 
non-Hodgkin’s lymphoma because it elicits ADCC (23, 24).  Consequently, making 
HD8 as IgG4 antibody is likely to eliminate its anti-tumor ADCC activity as well.  We 
were then faced with the problem that modifications of the Fc region that eliminate 
CDC may also affect ADCC since the C1q-binding site overlaps with the Fc 
receptor-binding site (19-21, 25-27).  However, when we substituted residues 322 and 
331 in the HD8 Fc region – these residues do not overlap exactly with the Fc 
receptor-binding site (Figure 2-1) – the CDC function of the antibody was lost while 
both its ADCC and in vivo anti-tumor functions were retained.  Moreover, the modified 
antibody did not induce infusion reactions in cynomolgus monkeys at the massive dose 
of 50 mg/kg, which exceeds the lethal dose of HD8-IgG1 (1.5 mg/kg) by 30-fold.  
These results suggest that similar modifications may be useful for other antibodies 
whose therapeutic use is limited by their propensity to induce infusion reactions.  
Moreover, these results further support the notion that infusion reactions are largely 
caused by CDC.  
Klingbeil and Hsu have shown previously that the humanized IgG1 anti-HLA-DR 
antibody Hu1D10 induces severe infusion reactions in monkeys (12).  Moreover, in 
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clinical trials with this antibody, some patients suffered infusion reactions and had to be 
given anti-anaphylactic medications (13).  Such concerns are serious impediments to 
the clinical use of HLA-DR-targeting drugs for treating B-cell malignancies, including 
non-Hodgkin's lymphoma.  Thus, our modified HD8-IgG1-Ala322Ser331 
anti-HLA-DR antibody may be highly useful in the clinic. 
To test the effect of the Fc modifications on the ability of HD8 to induce CDC and 
ADCC and control tumor growth in vivo, we established a novel infusion reaction rat 
model.  The WKAH rat strain that was used was selected because preliminary studies 
revealed its PBMCs were strongly recognized by HD8; moreover, there was high 
homology between the HD8 epitope (15) and the MHC class II sequences of the rats.  
That HD8 acts similarly in both this rat model and the cynomolgus monkey model was 
revealed by the fact that it had similar ADCC and CDC bioactivities in vitro and 
induced similar infusion reaction symptoms in both species.  The rat model did differ 
from the monkey model in that the antibodies were administered by bolus injection 
rather than by slow infusion; the former method permits the administration dose for the 
induction of infusion reaction to be lowered. 
Despite the strong correlation between infusion reaction severity and the CDC 
activity of the HD8 antibody, it is likely that other immune mechanisms also contribute 
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to infusion reactions since our modified CDC-incompetent antibody still induced some 
mild infusion reactions in the rat model.  One possible additional mechanism is that the 
binding of HD8 antibodies to HLA-DR on mast cells activates them; indeed, it has been 
shown that such binding induces ultrastructural mast cell changes that suggest they are 
induced to secrete granules (28).  However, this possibility is less likely since the Fab 
fragment of the HD8 antibody did not induce infusion reactions in the rat model.  
Moreover, a IgG4-type anti-HLA-DR antibody does not induce infusion toxicity on 
monkeys (14).  Thus, it is unlikely that the direct binding of the antibody to HLA-DR 
plays a significant role in inducing infusion reactions.  The additional mechanisms 
contributing to infusion reactions remain to be elucidated. 
In conclusion, we demonstrated that (a) the severity of infusion reactions induced by 
an anti-HLA-DR antibody correlate strongly and positively with its ability to evoke 
CDC, and that (b) the substitutions of two amino acids in the Fc region, which diminish 
CDC, also reduce the risk of infusion reaction without diminishing the anti-tumor 
activity of the antibody. 
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CONCLUSIONS 
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HLA-DR is a well-known antigen that is highly expressed on B cell malignancies.  
However, targeting HLA-DR by antibody has to overcome a potential diversity of 
binding characteristics due to the high polymorphism of the antigen.  Among the 
newly-generated fully-human antibodies, one clone HD8 was selected and characterized 
precisely.  The HD8 antibody was found to possess a wide reactivity on 
HLA-DR-positive cells, suggesting its high potential as a therapeutic agent.  The HD8 
antibody, unexpectedly but in a way similar to the former HLA-DR antibody, induced 
severe toxicity on monkeys known as “infusion reaction”.  Then, the infusion reaction 
induced by the HD8 antibody and its properties were carefully investigated and found to 
be ameliorated by the modification of the antibody. 
The following features are the principal results obtained in the present study: 
1.  The anti-HLA-DR antibody HD8, which was originally obtained from a 
human IgG-producing mouse, exerted a wide reactivity on HLA-DR-positive 
cells, and strong efficacies on in vitro cytotoxicity assays and in vivo xenograft 
models. 
2.  The HD8 antibody was revealed to possess its binding specificity on the 
conserved amino acids in the variable region of hyper-polymorphic HLA-DR 
E chain through precise immunoblot analyses.  The result further revealed 
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that the antibody recognizes a wide variety of MHC class II molecules, i.e., 
99.2% of HLA-DRB alleles, 100% of HLA-DPB alleles and 66% of 
HLA-DQB alleles. 
3.  The HD8 antibodies with IgG1- and IgG2-Fc domains have been found to 
induce severe infusion reactions in monkeys and rats by intravenous 
administrations.  The severity of the infusion reactions was correlated 
strongly with their abilities to evoke CDC. 
4.  The substitutions of two amino acids in the Fc domain of HD8-IgG1 at 
Lys322Ala plus Pro331Ser significantly decreased the intensity of infusion 
reactions in the rat model significantly.  Moreover, the modified antibody 
induced no infusion reactions in monkeys at all. 
 
In addition to the observations that the complement was a key factor of the infusion 
reaction, the existence of other mechanisms was also suggested by the rat study.  The 
potential mechanisms of the infusion reaction can be cytokine release, histamine release, 
and so on, which should be elucidated in future studies. 
 
In brief, the modified antibody HD8-IgG1-Ala322Ser331 was suggested as a 
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hopeful clinical candidate against B cell malignancies, based on its following 
characteristics: a fully-human structure, a wide recognition to MHC class II, high 
efficacies in in vitro/vivo studies, and a reduced toxicity of infusion reaction.  
Moreover, a useful option of antibody modification to decrease CDC was provided, 
when one needs to reduce some risks of infusion reactions of antibodies without losing 
ADCC as an anti-tumor activity. 
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